Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Excel spreadsheet display of new data from MDA
View:
Post by DJDawg on Apr 27, 2023 12:39pm

Excel spreadsheet display of new data from MDA

I made an excel table using the MDA data. Shows the MDA swimmers plot. I sorted the patients into how they started (CR, IR, NR) so can see the flow over time.

https://postimg.cc/xkH2XP87

What we can all see is that there is something like a 54% to 65% chance of a brand new patient being CR (depends on whether you include some of the under-treated). That is good. We can see that some CR's drop off but there is good recurrence free survival. I like that there is a nice pipeline of CR's in the excel screenshot who are at 90 and 180. That is good news.

We can all see that there has never been a patient that started IR or NR that was anything other than NR at 450. To show this I just removed the 180,270,360 colums.

https://postimg.cc/hfk7YThr

Good luck to all.
Comment by ScienceFirst on Apr 27, 2023 12:53pm
DJDawg ... Great work.  Great visualization.  Thanks for sharing.
Comment by NotinKansas on Apr 27, 2023 1:21pm
Thanks DJDawg, great job. I just finished going through the numbers myself. Here's what I got from that: The data presented (for a welcome change) is internally consistent: all #s and %s presented in the tables can be derived from the swimmers’ plot (use the verticals to arrive at the CR/IR numbers and rates presented in the tables). The reduction in evaluable patients imo results not ...more  
Comment by DJDawg on Apr 27, 2023 1:25pm
thanks for your thoughtful input NotinKansa. I lined up the ASCO data and the AUA data and thought I would be able to match up all the patients but I had trouble. Are you saying that you were able to do so?
Comment by NotinKansas on Apr 28, 2023 12:23am
Hi DJDawg, I tend to look at data presented in MD&A's alone - not suggesting those are more reliable, just to keep things manageable for myself. From these, I take whatever raw numbers they include (i.e. # of treated patients, evaluable patients, CRs, IRs, etc.) and I keep track of how they develop from MD&A to MD&A. I typically exclude the Phase Ib results (assuming they won't ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250